MedTrace Logo

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

NCT04849416 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2026-02-06

Study results available
· View outcomes & findings →

Summary

A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.

Conditions

  • Leukemia, Lymphoid
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Mantle-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, B-Cell
  • Lymphoma, B-Cell, Marginal Zone
  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

LOXO-305

Administered orally.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-14
Primary Completion
2023-04-10
Completion
2025-12-29
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04849416 on ClinicalTrials.gov